U.S. Court Invalidates Teva's Copaxone Patent

The 2-1 decision by the U.S. Court of Appeals for the Federal Circuit is a blow to the Israeli drug giant in its seven-year fight over patent protections for Copaxone.

Andrew Chung
Send in e-mailSend in e-mail
An employee collects newly manufactured pills at the tablet production plant at Teva Pharmaceutical headquarters in Jerusalem in 2011.Credit: Adam Reynolds/Bloomberg